Teriflunomide
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published June 10, 2013.
Author Disclosures
- Jiwon Oh, MD, FRCPC and
- Paul W. O’Connor, MD, MSc, FRCPC
- Jiwon Oh, MD, FRCPC and
(1) EMD-Serono, Scientific advisory board
NONE
(1) Teva Neurosciences, Educational travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Multiple Sclerosis Society of Canada Transitional Career Development Award
NONE
NONE
NONE
NONE
NONE
NONE
- Paul W. O’Connor, MD, MSc, FRCPC
Novartis Fingolimod Steering Committee--member--2007-present, Teriflunomide Steering Committee ( sanofi aventis)--chairman--2006-present, Bayer BEYOND study steering committee--chairman--2007-2009, BRAVO (laquinimod) study DMC--chairman--2007-present, Genentech advisory board--member, Roche advisory board, Receptos advisory board, Actelion advisory board
NONE
Funding for travel or speaker honoraria: 1 Biogen Idec-ECTRIMS meeting Dusseldorf--2009--presentations of data from two studies, 2 Teva--Meeting in London--advise and present data on safety of MS drugs--2009, 3 Advisory board meeting in Montreal 2010
NONE
NONE
NONE
NONE
Biogen Idec consultant 2007-2012, Actelion consultant 2010, Bayer Consultant 2007-2009, EMD Serono Consultant 2009-11, Teva Consultant 2007-2012, Genentech Consultant 2007-2008, Sanofi Genzyme Consultant 2002-2012, Novartis Consultatn 2005-2012, Warburg Pincus Consultant 2009
NONE
NONE
NONE
1 Bayer--study grant support for BEYOND study--2006-82 Novartis--study grant support for FREEDOMS, TRANSFORMS and INFORMS study--2006-2012, 3 BIOMS--study grant support 2006-9, 4 Sanofi Aventis-grant supprot for TEMSO, phase 2 , CIS and nerispirdine studies, 5 ROCHE; grant supprot for phase 2 OCRELIZUMAB study, 6 Biogen Idec: grant support for ASCEND and JEMS study, 7 Roche grant support for OPERA and ORATORIO studies
NONE
NONE
National Scientific and Clinical Advisor to to the MS Society of Canada. 2008-2009 (ongoing)
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurology (JO), Johns Hopkins University, Baltimore, MD; and Division of Neurology, Department of Medicine (JO, PWO), St. Michael's Hospital, University of Toronto, Toronto, Canada.
- Correspondence to:
oconnorp{at}smh.ca
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.